The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
AnaptysBio COM 032724106 18,833 180,950 SH   SOLE   180,950 0 0
Argenx COM 04016X101 27,879 346,792 SH   SOLE   346,792 0 0
Ascendis Pharma A/S COM 04351P101 38,337 586,195 SH   SOLE   586,195 0 0
AveXis Inc COM 05366U100 127,986 1,035,657 SH   SOLE   1,035,657 0 0
Bellerophon Therapeutics COM 078771102 8,631 4,149,378 SH   SOLE   4,149,378 0 0
BioCryst Pharmaceuticals Inc COM 09058V103 10,594 2,220,971 SH   SOLE   2,220,971 0 0
Biohaven Pharmaceuticals COM G11196105 35,816 1,390,391 SH   SOLE   1,390,391 0 0
Catalyst Biosciences COM 14888D109 14,284 553,629 SH   SOLE   553,629 0 0
DBV Technologies COM F2927N109 18,129 616,217 SH   SOLE   616,217 0 0
Endocyte Inc COM 29269A102 39,087 4,300,000 SH   SOLE   4,300,000 0 0
Menlo Therapeutics COM 586858102 12,777 340,000 SH   SOLE   340,000 0 0
Momenta Pharmaceuticals COM 60877T100 7,714 425,000 SH   SOLE   425,000 0 0
Obseva SA COM H5861P103 28,920 2,143,843 SH   SOLE   2,143,843 0 0
Ra Pharmaceuticals COM 74933V108 2,892 544,612 SH   SOLE   544,612 0 0
Savara Inc COM 805111101 1,103 119,840 SH   SOLE   119,840 0 0
Spero Therapeutics Inc COM 84833T103 6,920 485,615 SH   SOLE   485,615 0 0
Zogenix COM 98978L204 14,499 362,010 SH   SOLE   362,010 0 0